Rad AI
Rad AI is the leader in generative AI solutions for radiology, transforming the way radiologists work and improving patient care. The company’s flagship product, Rad AI Reporting, streamlines radiology reporting with AI-driven technology and empowers radiologists to achieve greater efficiency, accuracy, and satisfaction. Rad AI Impressions, the company’s pioneering product, established Rad AI as an innovator in generative AI for radiology; as the first generative AI application to achieve widespread adoption in radiology, it is now trusted by thousands of U.S. radiologists. Rad AI Continuity, the most comprehensive solution of its kind, provides AI-driven patient follow-up. Rad AI is the fastest-growing radiologist-led AI company and has been recognized as one of the most promising healthcare AI companies by CB Insights (Digital Health 50, AI 100) and AuntMinnie (Best New Radiology Software of 2023, Best New Radiology Vendor of 2021). An Accenture report in December 2023 highlighted Rad AI as having the highest influence score and brand buzz of any private company in radiology, solidifying its position as a leader in the field.
Qure.Ai Technologies Inc.
Qure.ai is a health tech company that uses deep learning and Artificial Intelligence (AI) to make healthcare more accessible and equitable for patients worldwide. Our solutions power the efficient identification and management of Tuberculosis (TB), Lung Cancer and Stroke to support clinicians and propel developments in the pharmaceutical and medical device industries. We empower healthcare by helping to identify conditions fast, prioritize treatment planning and ultimately improve quality of patient life. | About Qure.ai Qure.ai is a global health tech company that innovates AI-enabled healthcare solutions to drive early clinical diagnosis and boost seamless patient care coordination. Qure’s solutions power the efficient identification and management of TB, Lung Cancer and Neurocritical findings to support clinicians and propel developments in the pharmaceutical and medical device industries. The company empowers healthcare workers or health systems by helping to identify conditions fast, prioritize treatment planning and ultimately improve quality of patient life. Qure.ai has deployments in over 100 countries, with regional offices in New York, London, Dubai and Mumbai. It is a TIME100 Most Influential Company 2025.
QUIBIM S.L.
QUART X-Ray QA Solutions
Complete solutions for your x-ray Quality Control and Quality Assurance operations, including: – Diagnostic X-Ray Control Instrumentation / Diagnostic Dosemeters – Test Phantoms and Quality Check Objects for x-ray system performance and image quality – Meters for Radiation Protection – Personal Dosimeters
Quanttrace
Quanttrace: Pioneering Non-Invasive Therapeutic Drug Monitoring Quanttrace is a spin-off from the Laboratory of Neuroengineering at the National University of San Martín (UNSAM, Buenos Aires, Argentina). We are pioneers in non-invasive therapeutic drug monitoring, developing devices that personalize healthcare without interfering with patients’ daily lives. Successful pharmacological treatment relies on patient adherence. However, even perfect adherence can’t prevent plasma level variability due to individual differences in absorption, metabolism, and sensitivity. Personalized medicine aims for optimal drug levels tailored to each individual, especially for medications with narrow therapeutic ranges (such as oncologic drugs, antipsychotics, anticonvulsants, and antibiotics). Our challenge at Quanttrace is to provide the pharmaceutical and biotech industries with in-situ methods for measuring plasma concentrations without disrupting daily routines. Our technology is wearable, non-invasive, and works in everyday environments without laboratory equipment. Data is processed on a mobile device, and results are immediate. Quanttrace merges complex signal analysis and AI tools with advanced medicinal chemistry, allowing patients and caregivers to monitor plasma drug concentration at home and communicate directly with their doctors. This represents a significant advancement towards precision medicine and in-situ dose control, ensuring optimal treatment adherence. At Quanttrace we are currently conducting preclinical trials in small and large animals to validate our technology. At this stage, we have filed a provisional patent to protect our innovation. Right now we are actively seeking investment to refine our development and successfully conclude our preclinical trials and go into a clinical phase of research. We are open to hearing from investors who wish to partner with us in this innovative and exciting research pipeline. keywords: personalized medicine, precision medicine, precision healthcare, patient monitoring device, in-situ dose control, therapeutic drug monitoring, artificial intelligence, AI, medicinal chemistry, at home monitoring.
QUANTOOM BIOSCIENCES
Quantoom Biosciences, is reinventing mRNA production by developing an RNA Platform that encompasses DNA and RNA manufacturing and formulation, along with critical reagent supply, from sequence to large scale production. Quantoom’s approach to the production of mRNA vaccines involves redesigning the entire manufacturing process from start to finish. By doing this, Quantoom Biosciences can produce mRNA vaccines faster, more efficiently, and at a lower cost than traditional methods. | Quantoom Biosciences is a full-stack RNA partner for mRNA- and saRNA-based vaccines and therapeutics. Its N-Force toolbox relies on 3 core elements to turn any antigen into a (sa)mRNA-LNP drug product: Ncode for sequence design and optimization, Ntensify® for RNA production and NcapsulateTM for RNA-LNP formulation. Launched in 2023, the Ntensify solution enables fully integrated, scalable RNA production by combining processes, equipment, reagent mixes, and disposables and has gained global adoption, being recognized for performance and ease-of-use. Beyond technology, Quantoom Biosciences assists its partners by providing extensive enabling solutions, ranging from strategic R&D partnerships to sequence design & optimization.
QuantalX Neuroscience Ltd
At QuantalX™, we are redefining brain healthcare by empowering clinicians with real-time, accurate insights that eliminate guesswork and accelerate decision-making. Our mission is to close critical diagnostic gaps and enable earlier, more precise intervention for neurological conditions. We envision a future where functional brain assessments are accessible at every point of care, transforming how brain disorders are detected, managed, and treated. We aim to set a new gold standard in neurodiagn
Qoolabs Inc
Qoolabs is dedicated to providing innovative antibody products with focus on recombinant rabbit monoclonal antibodies. With our cutting-edge technology QMAb™ quick monoclonal antibody discovery platform, we provide top-notch antibody solutions. The QMAb™ platform is highly customizable to meet the unique needs of each of our clients. Whether you’re searching for antibodies to small molecules or specific epitopes, reach out to Qoolabs for the finest antibodies.
Qnity
The pharmaceutical sector and the clinical diagnostics market face longstanding bottlenecks that hinder innovation and deepen health inequalities. Drug discovery—a crucial step in the development of new therapies—is marked by inefficiencies in identifying and validating molecular interactions, especially when it comes to small molecules. Despite accounting for approximately 90% of approved drugs, these molecules exhibit subtle interactions that require highly sensitive assays to detect. Traditional approaches, such as fluorescence- or radiolabel-based techniques, lose effectiveness at very low concentrations, compromising accuracy and significantly increasing development time and costs. Today, it is estimated that only 1 in every 10,000 compounds tested ultimately receives approval as a drug. This highly inefficient funnel contributes to an average cost of $2.6 billion and a timeline of 10 to 15 years to bring a new drug to market. In the diagnostics field, the challenges are equally severe. Tests based on outdated methods lack sensitivity, scalability, and accuracy—rendering them either inaccessible or ineffective, especially in regions with limited infrastructure. Inaccurate or delayed diagnoses lead to inappropriate clinical decisions, further deepening health inequalities and compromising the effectiveness of public policies and individual treatments. These systemic inefficiencies not only generate multi-billion-dollar costs but also limit scientific progress and restrict millions of people from accessing quality therapies and diagnostics. There is an urgent need for new tools that enable significant advances in precision, cost-efficiency, and speed at the intersection of science, industry, and public health. Qnity offers a proprietary quantum electrochemical sensor technology based on a gold monolayer functionalized with a molecule developed through a collaboration between São Paulo State University (UNESP) and the University of Oxford. This molecule possesses unique quantum properties that dramatically amplify the system’s sensitivity, enabling the detection of molecular interactions with exceptional precision. The sensor’s operation is both simple and powerful. The functionalized electrode surface is anchored to a biological receptor—such as a protein, DNA, or another molecular target—and then exposed to various analytes (such as small molecules, antibodies, or DNA fragments). The system measures the strength, specificity, and dynamics of these interactions through electrochemical signals modulated by the sensor’s quantum properties. Unlike other approaches, such as Surface Plasmon Resonance (SPR), which operate at the picomolar scale (10⁻¹² M), Qnity’s technology reaches sensitivity levels in the attomolar range (10⁻¹⁸ M)—six orders of magnitude more sensitive. This capability allows for the detection of extremely weak and rare interactions, with direct implications for the discovery of new drugs and biomarkers. Moreover, the platform enables comprehensive molecular affinity analyses and, in the future, may include binding kinetics and thermodynamic properties—all with high reproducibility, low per-assay cost, and scalability for multiple targets. Qnity’s innovation stands on three key pillars: sensitivity, accessibility, and cost. Unprecedented sensitivity: Our technology surpasses the sensitivity of current methods like SPR by up to one million times, enabling the identification of critical interactions that previously went unnoticed. Drastically reduced cost: Qnity’s instrumentation is up to six times more affordable than commercial SPR systems. Additionally, the per-analysis cost is up to 600 times lower, enabling large-scale use even in resource-limited settings. Technological accessibility: Qnity’s compact design, user-friendly interface, and modular architecture make it suitable for both cutting-edge laboratories and research centers in underserved regions, directly contributing to the democratization of innovation. Qnity is a real and immediate application of quantum science to expand equitable access to healthcare. Our technology dramatically lowers the cost of discovering and validating new drugs while improving accuracy and speed in clinical diagnostics. As a result, we not only accelerate the arrival of new treatments to the market but also make their adoption economically viable in regions that have historically lacked access to this kind of innovation. The platform is compatible with different types of samples and protocols and is highly customizable for local needs—from cancer to Alzheimer’s disease, dengue to neglected tropical diseases. Qnity’s mission is to radically transform the processes of drug discovery and diagnostic testing. Our impact spans multiple sectors: Pharmaceutical companies benefit from a faster, more cost-effective, and more precise platform for screening candidate compounds, reducing the time and risk involved in drug development. ademic researchers gain access to a versatile and powerful tool for fundamental investigations into biomolecular interactions, with the potential to drive discoveries across many areas of bioscience. Vulnerable populations are the greatest beneficiaries. By lowering the cost and increasing the accuracy of new therapies, our technology enables access to quality healthcare even in areas with limited infrastructure. Qnity is currently in a pre-commercial validation phase with academic and industrial partners. We have already established strategic collaborations with renowned research institutes such as the UNESP Institute of Chemistry. Our goal is to complete prototype testing under real-world conditions, optimize scalability, and begin small-scale production for early adopters in 2026. Qnity offers much more than a new scientific tool—we deliver a new way of thinking about drug discovery based on the precision and power of quantum electrochemistry. By addressing one of the most critical bottlenecks in the healthcare industry with an accessible, scalable, and validated solution, Qnity positions itself as a catalyst for a new era in biomedical innovation. Investing in Qnity is investing in the future of global health—faster, more accurate, and more equitable.
QIAGEN
QIAGEN pushes the boundaries of innovation to improve our understanding of DNA, RNA and proteins – the building blocks of life. We enable our customers to unlock valuable insights from any biological sample – be it blood, a throat swab or many other materials. We support their success with a broad range of products for molecular testing, serving applications from basic life sciences research to clinical healthcare. Never before have QIAGEN’s molecular testing solutions made a stronger impact on people’s lives than in the global fight against COVID-19. It is one of the many ways we are advancing science and improving outcomes for people across the world. We are known for highest quality products and outstanding service from a global organization of 6.000 passionate people in 35 countries. Our reputation is based on confidence in decisions, clarity of results and pride in the insights our customers achieve. More than 35 Nobel Prize winners among more than 500,000 customers worldwide are proof of that success. We will continue to define the advancements of tomorrow – in line with our vision of making improvements in life possible. Discover more at http://www.qiagen.com.